Financial Performance - The company's revenue for Q1 2023 was CNY 1,178,806,488.43, representing an increase of 18.76% compared to CNY 992,593,188.54 in the same period last year[3] - Net profit attributable to shareholders was CNY 227,429,413.46, up 20.53% from CNY 188,688,696.04 year-on-year[3] - The net cash flow from operating activities reached CNY 364,395,839.44, reflecting a growth of 27.34% compared to CNY 286,170,933.07 in the previous year[3] - Total operating revenue for Q1 2023 reached CNY 1,178,806,488.43, an increase of 18.7% compared to CNY 992,593,188.54 in Q1 2022[18] - Operating profit for the quarter was CNY 261,579,559.01, representing a 24.7% increase from CNY 209,692,665.09 in Q1 2022[19] - Net profit attributable to the parent company was CNY 227,429,413.46, up 20.6% from CNY 188,688,696.04 in the same period last year[19] - Basic earnings per share for Q1 2023 is CNY 0.484, up 10% from CNY 0.44 year-on-year[14] - Earnings per share for the quarter were CNY 0.23, up from CNY 0.19 in the same period last year[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,815,268,549.17, an increase of 5.15% from CNY 6,481,745,574.76 at the end of the previous year[3] - The total assets as of March 31, 2023, amount to CNY 6,815,268,549.17, an increase from CNY 6,481,745,574.76 at the beginning of the year[16] - The total liabilities as of March 31, 2023, are CNY 906,092,526.39, compared to CNY 793,943,159.84 at the beginning of the year[16] - Total liabilities increased to CNY 1,005,339,007.70, up from CNY 896,989,429.48, indicating a rise of 12.1%[19] - The company's total equity attributable to shareholders reached CNY 5,849,678,037.83, compared to CNY 5,622,248,624.37, marking an increase of 4.0%[19] Cash Flow - The company reported a decrease of 107.70% in net increase in cash and cash equivalents, influenced by cash flows from operating, investing, and financing activities[8] - Cash and cash equivalents at the end of Q1 2023 are CNY 1,519,601,953.76, slightly down from CNY 1,532,214,418.85 at the beginning of the year[15] - Cash inflow from financing activities was 25,000,000.00 CNY, unchanged from the previous year[22] - Cash outflow for financing activities was 15,969,215.29 CNY, slightly down from 16,437,185.78 CNY in the previous year[22] - The company reported a decrease in cash and cash equivalents by 14,166,509.61 CNY during the quarter[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,244, with the largest shareholder holding 35.15% of the shares[9] - The company has a significant shareholder structure, with the top 10 shareholders holding a combined 55.58% of the shares[11] Investment Income - Investment income from financial products was CNY 11,360,194.34, indicating a significant increase of 475.22% year-on-year due to higher returns from financial investments[5][7] - The company recorded investment income of CNY 15,867,492.31, significantly higher than CNY 2,758,525.71 in Q1 2022[19] Tax and Expenses - The company experienced a 55.13% increase in income tax expenses, attributed to higher total profits and deferred tax assets[7] - Research and development expenses amounted to CNY 109,676,566.12, an increase of 8.2% from CNY 100,832,530.58 in Q1 2022[18] Future Outlook - The company expects a positive performance outlook for the first half of 2023, with an upward trend in operating results[13] Other Information - The company did not undergo an audit for the first quarter report[23] - The cash flow from operating activities was not detailed in the provided documents[22]

江苏恩华药业股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 1、公司参与人员：公司总经理孙家权、独立董事陈国祥、董事会 | | | 秘书段保州、财务负责人李岗生。 | | | 2、参与的投资者详见附件。 | | 时间 | 2023 年 3 月 28 日下午 15:00-17：00 | | 地点 | 全景网"投资者关系互动平台" （https://ir.p5w.net） | | 形式 | 采用网络远程的方式 | | 交流内容及具体问答记 | 详见附件。 | | 录 | | | 关于本次活动是否涉及 | 本次活动未涉及应披露重大信息。 | | 应披露重大信息的说明 | | | 活动过程中所使用的演 | 无。 | | 示文稿、提供的文档等 | | | 附件（如有，可作为附 | | | 件） | | 附件： 江苏恩华药业股份有限公司 2022 年度业绩说 ...

Financial Performance - The company's operating revenue for 2022 was ¥4,298,513,062.14, representing a year-on-year increase of 9.22% from ¥3,935,664,219.52 in 2021[13]. - The net profit attributable to shareholders for 2022 was ¥900,926,029.55, which is a 12.93% increase compared to ¥797,777,327.57 in 2021[13]. - The basic earnings per share for 2022 was ¥0.89, up 12.66% from ¥0.79 in 2021[13]. - The total assets at the end of 2022 amounted to ¥6,481,745,574.76, reflecting a 13.77% increase from ¥5,697,186,706.05 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥5,622,248,624.37, which is a 14.26% increase from ¥4,920,688,031.43 at the end of 2021[13]. - In Q4 2022, the operating revenue reached ¥1,178,387,350.86, with a net profit attributable to shareholders of ¥159,051,214.46[16]. - The company reported a cash flow from operating activities of ¥861,023,149.69 for the year 2022, which is a 22.81% increase from ¥701,117,596.67 in 2021[13]. - The company recognized government subsidies amounting to ¥46,912,734.05 in 2022, compared to ¥32,743,590.42 in 2021[17]. - The weighted average return on equity for 2022 was 17.20%, slightly down from 17.69% in 2021[13]. - The company reported a total of ¥28,166,708.35 in non-recurring gains and losses for 2022[17]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares to all shareholders, based on a total of 1,007,588,092 shares[2]. - The proposed cash dividend for 2022 is ¥2.00 per 10 shares, totaling ¥201,517,618.40, with no stock dividends or capital reserve transfers[133]. - The cumulative cash dividend amount from 2019 to 2021 was approximately ¥604.19 million, accounting for 82.77% of the average annual net profit during the same period[153]. - After the dividend distribution, the retained undistributed profit will be ¥3,776,835,195.20, to be carried forward for future distribution[133]. Market and Industry Trends - The pharmaceutical industry in China is experiencing significant growth, with healthcare expenditure as a percentage of GDP reaching 4.83% in 2022, indicating a rising demand for medical services[21]. - Chronic disease prevalence in China has reached 23%, with chronic diseases accounting for 86% of total deaths, leading to increased long-term medication and healthcare costs[21]. - The central nervous system (CNS) drug market in China is still in its early stages, with only 3% of the global CNS drug consumption, compared to 49% in the US and 26% in Europe[23]. - The aging population and rising health awareness among the public are expected to drive further growth in the pharmaceutical sector, presenting significant opportunities for companies like Jiangsu Enhua[22]. - The ongoing healthcare reforms and policies, such as centralized procurement, are pushing pharmaceutical companies to innovate and improve their R&D capabilities[21]. Research and Development - The company has a robust product pipeline with 22 innovative drug projects and 38 generic drug projects currently under development, alongside 15 projects undergoing consistency evaluation[23]. - The company increased R&D investment to CNY 495,383,504.42, a growth of 23.10% compared to the previous year, with over 70 ongoing research projects[30]. - There are currently 22 innovative drug projects under development, including 1 in Phase II clinical trials and 4 in Phase I clinical trials, with 5 projects expected to submit clinical applications in 2023[30]. - The company has launched 38 generic drug projects, with 2 generic drug production approvals obtained during the reporting period[30]. - The company has applied for 127 invention patents and received 44 authorized invention patents during the reporting period[30]. Corporate Governance - The company reported a commitment to improving corporate governance, aligning with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange, enhancing internal control systems[97]. - The board of directors consists of four independent directors, exceeding one-third of the total board members, ensuring compliance with governance standards[98]. - The company has established a mechanism to prevent major shareholders from occupying company funds, safeguarding the interests of minority shareholders[97]. - The company emphasizes transparent communication with investors, implementing various channels for interaction, including online platforms and direct communication[99]. - The company has a comprehensive human resources management system that includes detailed regulations on recruitment, training, compensation, and performance evaluation[154]. Environmental Responsibility - The company strictly adheres to environmental protection laws and regulations, ensuring wastewater and air emissions meet national standards[143]. - The company invested approximately CNY 15.22 million in environmental governance and protection, including the purchase of environmental protection equipment and facility upgrades[151]. - The company implemented a wastewater treatment system with a capacity of 800 tons per day at the Jinshanqiao plant, ensuring that treated wastewater meets discharge standards[146]. - The company achieved over 95% efficiency in VOC treatment after upgrading its exhaust gas treatment systems, with an investment of CNY 3 million in 2022[147]. - The company has not faced any administrative penalties related to environmental issues in 2022[152]. Social Responsibility - The company actively participates in charitable activities, contributing medicines and funds to local poverty alleviation efforts, enhancing its social responsibility image[99]. - The company has established the "Enhua Caring Fund," which has donated a total of 807,800 yuan to assist socially disadvantaged families over the past seven years[159]. - The company collaborates with Nanjing Medical University to provide 60,000 yuan in scholarships annually to outstanding students in the field of psychiatry[159]. - The company has committed 480,000 yuan to support rural revitalization efforts, directly benefiting local communities[160]. - The company has been fulfilling its social responsibilities by supporting education, culture, science, and health initiatives in local areas[159]. Future Outlook - The company aims for approximately 15% growth in business revenue, total profit, and net profit in 2023 compared to the audited data of 2022[86]. - The company plans to advance 6 innovative drug clinical trials in 2023 and aims to establish 3-5 new innovative drug projects, with a goal of submitting 5 innovative drug applications for clinical trials[86]. - The company is focusing on high-barrier generic drugs and has 4 projects undergoing consistency evaluation, with 3 expected to be approved in 2023[87]. - The company is enhancing its marketing strategies to strengthen new product market access and aims to maintain its leading position in the central nervous system drug sector[88]. - The company is committed to optimizing production management and cost control, with a focus on improving product quality and reducing complaints[87].

江苏恩华药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002262 证券简称：恩华药业 公告编号：2023-012 江苏恩华药业股份有限公司（以下简称"公司"）定于2023年3月28日（星期二）15:00- 17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 公司出席本次说明会的人员有：公司总经理孙家权、董事会秘书段保州、财务负责人李 岗生、独立董事陈国祥。 问题征集专题页面二维码 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可于2023年3月27日（星期一）17：00前 访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。公司将在2022年度业 绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会 ...